Mackenzie A. Michell-Robinson, C. Moore, Luke M. Healy
Dec 2, 2015
Citations
4
Influential Citations
60
Citations
Quality indicators
Journal
Annals of Clinical and Translational Neurology
Abstract
Dimethyl fumarate (DMF), a therapy for relapsing‐remitting multiple sclerosis (RRMS), is implicated as acting on inflammatory and antioxidant responses within both systemic immune and/or central nervous system (CNS) compartments. Orally administered DMF is rapidly metabolized to monomethyl fumarate (MMF). Our aim was to analyze the impact of fumarates on antiinflammatory and antioxidant profiles of human myeloid cells found in the systemic compartment (monocytes) and in the inflamed CNS (blood‐derived macrophages and brain‐derived microglia).